PRECIGEN, INC. Construction in Progress, Gross
PRECIGEN, INC. (PGEN) had Construction in Progress, Gross of $328.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:ConstructionInProgressGross · last filed 2026-08-04
- 2026-06-30: Construction in Progress, Gross $328.00K.
- 2026-03-31: Construction in Progress, Gross $281.00K.
- 2025-12-31: Construction in Progress, Gross $278.00K.
- 2025-09-30: Construction in Progress, Gross $263.00K.
| Period end | Construction in Progress, Gross | Construction in Progress, Gross as first filed |
|---|---|---|
| 2026-06-30 | $328.00K 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $281.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $278.00K 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $263.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $10.44M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $10.13M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $9.02M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $8.38M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $8.11M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $7.31M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $1.58M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $892.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $106.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $151.00K 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $531.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $1.24M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.06M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $3.60M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $1.83M 10-K · filed 2023-03-06 | $3.82M 10-K · filed 2022-03-01 |
| 2021-09-30 | $2.73M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $2.19M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $2.53M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $2.75M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $3.67M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $4.80M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $5.38M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.23M 10-K · filed 2021-03-01 | $5.31M 10-K · filed 2020-03-02 |
| 2019-09-30 | $26.32M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $23.00M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $24.12M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $10.50M 10-K · filed 2020-03-02 | $18.88M 10-K · filed 2019-03-01 |
| 2018-09-30 | $18.66M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $17.22M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $15.82M 10-Q/A · filed 2018-08-13 | |
| 2017-12-31 | $14.11M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $15.14M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $12.49M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $7.16M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $4.51M 10-K · filed 2018-03-01 | $6.87M 10-K · filed 2017-03-01 |
| 2016-09-30 | $7.52M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.44M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $2.84M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $2.19M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $1.93M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.85M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $837.00K 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $1.00M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $404.00K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $140.00K 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $338.00K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $314.00K 10-K · filed 2015-03-02 | |
| 2013-09-30 | $10.00K 10-Q · filed 2013-11-07 | |
| 2012-12-31 | $14.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |